hPSC-based Regenerative Medicine by Innovative Technology Completely Overcoming Tumorigenicity

Platform technology with high through put design and development of tumorigenic cell-targeting lentiviral vector (TC-LV), and producing master cells

Proposals for screening and collaborative research on targets for amyloidosis treatment

Search for compounds that target the ubiquitination pathway of BRI2/BRI3, which is involved in the inhibition of aggregation of IAPP and amyloid-β involved in Alzheimer's disease.

A neuroprotective drug in new bismuth formulation

Project of formulation development from mechanism discovery

Efficient method for the production of liposomes containing hydrophilic substances

Efficient encapsulation of hydrophilic small molecules and medium molecular weight drugs such as nucleic acids and peptides in liposomes

Small molecule drug for myotonic dystrophy type 1 (DM1)

JM642, New small molecule targeting expanded CUG repeat RNA recover splicing defects in DM1.

Potent Solubilizer for Low-Solubility Aromatic Compounds and its Use

Solubilizer use for experimental formulation of low-solubility seed/hit compounds to evaluate the in vivo drug potency of such compounds.

Chronic Pain Mice Model without Nerve Injury

Temporary activation of astrocyte-neuron lactate shuttle (ANLS) sensitizes nociceptive transmission without nerve injury and remains neuropathic pain even after stopping the activation.

Liver organoid model containing human hepatocytes for pharmacokinetic assay

Original method and hepatocyte reproduced hepatobiliary function

Sustained-Release L-DOPA for Parkinson’s Disease

HPGCD for Niemann-Pick Type C (NPC) Therapy without Side Effects

Intrathecal HPGCD(2-Hydroxypropyl-γ-cyclodextrin) improving brain abnormalities in NPC patients without side effects